| 4-valent vaccination | 9-valent vaccination | ||
---|---|---|---|---|
 | Target | Calibration results | Target | Calibration results |
Female | ||||
Incidence | Â | Â | Â | Â |
 Cervical cancer | 6.12 | 6.12 | 7.48 | 7.48 |
 CIN 2+ | 63.15 | 22.29 | 114.23 | 27.62 |
 Vaginal | 0.56 | 0.05 | 0.67 | 0.05 |
 Vulvar | 0.44 | 0.08 | 0.50 | 0.08 |
 Anal | 1.37 | 1.37 | 1.42 | 1.42 |
 Genital warts | 127.08 | 126.93 | 127.08 | 126.93 |
 Head and Neck | 0.96 | 0.96 | 0.96 | 0.96 |
Mortality | Â | Â | Â | Â |
 Cervical cancer | 2.98 | 2.98 | 3.65 | 3.65 |
 Vaginal | 0.20 | 0.02 | 0.10 | 0.02 |
 Vulvar | 0.90 | 0.03 | 0.15 | 0.03 |
 Anal | 0.23 | 0.23 | 0.24 | 0.24 |
Male | ||||
Incidence | Â | Â | Â | Â |
 Penile cancer | 0.41 | 0.41 | 0.41 | 0.41 |
 Anal cancer | 0.76 | 0.76 | 0.79 | 0.79 |
 Genital warts | 131.85 | 131.52 | 131.85 | 131.52 |
 Head and Neck | 4.23 | 4.25 | 4.23 | 4.25 |
Mortality | Â | Â | Â | Â |
 Penile cancer | 0.10 | 0.10 | 0.10 | 0.10 |
 Anal cancer | 0.23 | 0.22 | 0.24 | 0.23 |